Peptonic Medical AB (publ) has received notification that the Australian patent office has granted the FOAM II patent. This patent provides broad protection for Peptonic's self-care product Vernivia, an over-the-counter and antibiotic-free treatment for bacterial vaginosis, as well as the company's mousse-based drug delivery technology Venerol. The patent extends until May 2038, ensuring Vernivia's market exclusivity.

Bacterial vaginosis is very common, especially among women of reproductive age, affecting approximately one in three women. Vernivia is the first clinically proven self-care treatment without antibiotics that provides rapid symptom relief, treats the vaginal infection, and simultaneously stimulates the growth of protective lactobacilli. The FOAM II patent family protects Peptonic's technology platform Venerol, which underpins Vernivia - the company's over-the-counter self-care treatment for bacterial vaginosis and/or symptomatic treatment of malodorous discharge.

The FOAM II patent has previously been granted in several countries, including Europe, the USA, China, Japan, and Korea. Patent applications have been submitted and are under review in for example Canada and Brazil.